Crossmark

How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options

Published Online: 2019-07-20

Published Print: 2019-08

Authors

Yeung, Cecilia C. S.

Shadman, Mazyar
License Information

Text and Data Mining valid from 2019-07-20

Version of Record valid from 2019-07-20
More Information

Article History

First Online: 20 July 2019

Compliance with Ethical Standards

:

: Cecilia C.S. Yeung has received research funding from Gilead for a study on idelalisib colitis. Mazyar Shadman has received research funding from MustangBio, Celgene, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, BeiGene, Acerta Pharma, and Merck, and has received compensation for service as a consultant from AbbVie, Genentech, Sound Biologics, Verastem Oncology, ADC Therapeutics, and Atara Biotherapeutics.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current